[exit] Penchant Research Library [3D]
Back to Search

RAP-103
B

Primary Mechanism CCR5 Inhibitor
Class Nootropic, Analgesic, Autonopotent
Drug Status Experimental
Alternate Names RAP103
Pubchem ID None/Unknown
Contributors @yana
Smiles: Unavailable
IUPAC: NH2- d-Thr - d-Thr - d-Asn - d-Tyr - d-Thr -COOH
CAS: None/Unknown

Pharmacology

RAP-103 is a long-lasting inhibitor of CCR5 (also CCR2/CCR8). Downstream inhibition of GSK-3β reactivates myelinating cells in the brain, improving LTP/cognition. This also enhances opioid analgesia and reduces anxiety.

It has been noted to be pretty subtle in subjective testing, with the dose range used of typically around 200-400mcg.

In studies, RAP-103 has been found to:

  • Inhibit neuropathic pain [1]
  • Reduce opioid reinforcement and physical dependence [2]

RAP-103 is experimental, however it has been well tolerated preclinically, and it is a peptide which likely improves its toxicity over small molecules.

Sources

[ 1 - Sci-Hub ] Neuropathic pain inhibitor, RAP-103, is a potent inhibitor of microglial CCL1/CCR8
[ 2 ] Multi-chemokine receptor antagonist RAP-103 inhibits opioid-derived respiratory depression, reduces opioid reinforcement and physical dependence, and normalizes opioid-induced dysregulation of mesolimbic chemokine receptors in rats

Related

No related nodes found